The number of Covid-19 infections in the US surpassed 10.4 million, with over 59 thousand patients in hospitals. This is the highest number of hospitalizations since July, as number of new infections continues to surge across the country. Over the last 24 hours, the US reported around 120 thousand new cases.
Meanwhile US Food and Drug Administration (FDA) has authorized the emergency use of Eli Lilly’s (LLY.US) experimental COVID-19 antibody treatment bamlanivimab for non-hospitalized patients with mild-to-moderate symptoms. New treatment reduces the need for hospitalization or emergency room visits in COVID-19 patients at high risk of the disease worsening.
The number of Americans with COVID-19 currently hospitalized has surged around 73% over the past 30 days to at least 59,275. Source: The COVID Tracking Project.
Eli Lilly’s (LLY.US) stock jumped over 3% in pre-market and is currently testing strong resistance at $148.00 which is additionally strengthened by 200 SMA (red line). If the current sentiment prevails, the upward move could be extended to the next resistance at $157.44. On the other hand local support lies at $139.21. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.